Peptides selectively lethal to malignant and transformed mammalian cells

verfasst von

Josef Michl, Jesko Koehnke, R Pincus, Matthew

Abstract

The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membranepenetrating leader sequence are also provided. The present invention also provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence operably linked to a nucleotide sequence encoding a subject peptide. Methods of selectively killing cancer cells in a subject by administering a therapeutically effective amount of a subject AdV vector are also provided by the present invention.

Organisationseinheit(en)

Institut für Lebensmittelchemie

Externe Organisation(en)

State University of New York (SUNY)

Typ

Patent

Publikationsdatum

23.09.2004

Publikationsstatus

Veröffentlicht

Ziele für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Elektronische Version(en)

https://worldwide.espacenet.com/patent/search/family/032987320/publication/WO2004081030A2?q=WO2004081030A2 (Zugang: Offen)